Single-incision belly-button surgery to remove kidney performed first at UT SouthwesternAugust 24, 2007Surgeons specializing in laparoscopic procedures at UT Southwestern Medical Center have successfully removed a patient's kidney by performing a unique nephrectomy entirely through the belly button. Dr. Jeffrey Cadeddu, associate professor of urology and radiology, performed the "single keyhole access" surgery, the first of its kind involving a kidney. The entire procedure was completed with only one incision and will leave the patient with a barely noticeable scar tucked in the umbilicus, or navel. "We are proud of this novel surgical technique," said Dr. Cadeddu, who leads the Clinical Center for Minimally Invasive Treatment of Urologic Cancer. "Laparoscopic surgery already gives patients smaller incisions, less pain and a faster recovery. This transumbilical technique is a further extension of laparoscopic surgery, which essentially removes scarring from the patient's skin."
Dr. Claus Roehrborn, chairman of urology at UT Southwestern, said, "Single-access surgery is the next major advance in making surgery even less invasive. For Dr. Cadeddu to be the first to perform such a surgery and remove the intact organ in this manner is a testament to the tremendous advances in clinical medicine that are being made at UT Southwestern and in our department." Dr. Roehrborn is director of the Sarah M. and Charles E. Seay Center for Pediatric Urology. Dr. Cadeddu performed the surgery with a newly developed set of high-dexterity instrumentation known as RealHand, manufactured by Novare Surgical Systems. The instruments enable surgeons to perform more difficult maneuvers that otherwise could not be completed. The high-dexterity instruments make it easy to manipulate and complete tasks regardless of whether the appliance is positioned over, under or around internal organs. Using the high-dexterity instrumentation, Dr. Cadeddu, who does not receive support from Novare, was able to place all of the standard laparoscopic entry points at the umbilicus. "The umbilicus is a circle. We put three holes next to each other - one at 12 o'clock, one at three o'clock, and one at six o'clock. I then connected the three of them together to make the hole large enough to take the kidney out," Dr. Cadeddu said. Most people have two kidneys, one on each side of the spine just above the waist. Each kidney is about the size of a small adult fist. Tumors and a rare kidney cancer, called transitional cell cancer, are the primary reasons for kidney removal. Historically, kidneys have been removed through an 8- to 10-inch incision from the middle of the abdomen to the back. Dr. Cadeddu said he believes the success of this new laparoscopic procedure and others like it are imperative as more physicians explore their options concerning natural orifice surgery. "We can now perform procedures using only one opening in the body, which can be hidden in a cosmetically advantageous or less painful location," Dr. Cadeddu said. "Our efforts to minimize invasive surgery led us to reduce the incision to a single hole." UT Southwestern Medical Center | |||||||||||||||||||||
|
Related Nephrectomy News Articles State's first single incision robotic kidney removal For the first time in Michigan, a diseased kidney has been surgically removed at Henry Ford Hospital using highly sophisticated 3D robotics through a single incision. St. Jude study offers new hope for children with kidney tumors deemed inoperable Physicians at St. Jude Children's Research Hospital have demonstrated that children with bilateral Wilms tumor, a cancer of the kidneys, can retain normal function in both kidneys by undergoing a procedure called bilateral nephron-sparing surgery, even when preoperative scans suggest that the tumors are inoperable. How less can be more when treating some kidney cancers A new Mayo Clinic study suggests that removing the entire kidney from younger patients with small kidney tumors may lead to decreased overall survival compared with an operation that removes the tumor but leaves the kidney intact. The study will be published in the February issue of the Journal of Urology. Study shows radiofrequency ablation highly effective in treating kidney tumors A relatively new, minimally invasive treatment was 100 percent successful in eradicating small malignant kidney tumors in a study of more than 100 patients, report researchers from Wake Forest University Baptist Medical Center. Glowing dye improves cancer removal in kidney A new way to provide clear images of cancerous tumors in the kidney during surgery promises to help physicians preserve as much kidney function as possible while still removing all the malignant tissue - a significant advance as doctors discover that saving as much healthy kidney tissue as possible is crucial for the future health of cancer patients. Cryoablation — A new treatment option for some kidney tumor patients Mayo Clinic researchers report that freezing kidney tumors through percutaneous cryoablation shows promise for patients who are not good candidates for surgery. Their early findings showing short-term success in more than 90 percent of selected patients are published in this month's issue of Radiology. Systemic treatment before surgery for kidney cancer prolongs patients' survival Preliminary results from a phase II clinical trial have provided the first evidence that treating people with kidney cancer with bevacizumab and erlotinib before surgery is safe, effective and may prolong patients' survival. Radical surgery for kidney cancer is risk factor for chronic kidney disease For forty years, the gold standard for treating a single, small tumor in the kidney has been to remove the entire kidney. Kidney cancer patients may be overtreated, U-M study finds A less aggressive type of surgery designed to spare healthy organ tissue is used infrequently to treat early-stage kidney cancer, according to researchers at the University of Michigan Comprehensive Cancer Center. Mayo Clinic finds kidney cancer patients are unlikely to respond to potential treatment drug Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs), is not likely to be effective for patients with high grade renal cell carcinoma - the most aggressive kidney cancer. More Nephrectomy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||